Volume 28, Number 11—November 2022
Research
Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents
Table 1
Characteristics among immunocompromised persons and LTCF residents in COVID-19 vaccine effectiveness study, South Korea, February–May 2022
Characteristics |
1st booster |
2nd booster |
|||||
---|---|---|---|---|---|---|---|
No. (%) participants |
Person-days |
No. (%) participants |
Person-days |
||||
Total |
736,439 |
39,175,439 |
236,010 |
5,197,160 |
|||
Sex | |||||||
F | 294,572 (40.0) | 16,096,170 | 94,864 (40.2) | 2,129,509 | |||
M |
441,867 (60.0) |
23,079,269 |
141,146 (59.8) |
3,067,651 |
|||
Age group, y | |||||||
18–39 | 33,010 (4.5) | 1,609,745 | 8,811 (3.7) | 196,656 | |||
40–59 | 171,954 (23.3) | 8,916,315 | 57,425 (24.3) | 1,233,939 | |||
60–74 | 332,987 (45.2) | 17,958,470 | 96,829 (41.0) | 2,165,276 | |||
>75 |
198,488 (27.0) |
10,690,910 |
72,945 (30.9) |
1,601,290 |
|||
Location | |||||||
Metropolitan area | 344,722 (46.8) | 18,053,072 | 95,738 (40.6) | 2,084,863 | |||
Nonmetropolitan area |
391,717 (53.2) |
21,122,367 |
140,272 (59.4) |
3,112,297 |
|||
Risk factors | |||||||
Immunocompromised | 477,215 (64.8) | 25,564,786 | 97,478 (41.3) | 2,132,538 | |||
Long-term care facility residents | 259,224 (35.2) |
13,610,653 | 138,532 (58.7) |
3,064,622 |
1These authors contributed equally to this article.